Zn-Shik-PEG nanoparticles alleviate inflammation and multi-organ damage in sepsis

Jie Guo, Yuqing Miao, Fayi Nie, Fei Gao, Hua Li, Yuan Wang, Qi Liu, Tingbin Zhang, Xiaohang Yang, Li Liu, Haiming Fan, Qiang Wang, Haifa QiaoJournal of Nanobiotechnology 2023 · DOI

TL;DR

This paper introduces novel Zn-Shik-PEG nanoparticles that overcome the limitations of shikonin, a promising anti-sepsis compound with poor solubility and high toxicity. These nanoparticles effectively scavenge reactive oxygen species (ROS) and suppress inflammation in sepsis models, demonstrating significant therapeutic potential for this life-threatening condition.

What Problem Does This Paper Address?

Sepsis is a critical medical emergency characterized by a dysregulated immune response leading to organ dysfunction and high mortality. A key contributor to sepsis pathology is the excessive production of reactive oxygen species (ROS) and an overactive inflammatory response. Shikonin, a natural compound, shows promise in combating both inflammation and ROS, but its clinical use is hindered by poor water solubility, low bioavailability, and significant toxicity. This research aims to address these limitations by developing a nanoparticle formulation of shikonin that enhances its therapeutic efficacy and safety for sepsis treatment.

Methods

The researchers employed an organic-inorganic hybridization strategy using metal-polyphenol coordination to create the Zn-Shik-PEG nanoparticles. Specifically, zinc ions (Zn<sup>2+</sup>) were coordinated with shikonin, forming a core structure. This core was then conjugated with polyethylene glycol (PEG) to improve biocompatibility and stability.

Key techniques used for characterization and evaluation included:

  • Transmission Electron Microscopy (TEM) and Dynamic Light Scattering (DLS) for nanoparticle size and morphology.
  • Energy-Dispersive X-ray Spectroscopy (EDS) mapping to confirm elemental distribution.
  • UV-Vis absorption spectroscopy to assess spectral characteristics.
  • Fourier-Transform Infrared (FTIR) spectroscopy and X-ray Photoelectron Spectroscopy (XPS) to analyze chemical composition and bonding.
  • Cell culture assays (RAW264.7 macrophages) to evaluate cytotoxicity, ROS scavenging (using DCFH-DA assay), and anti-inflammatory effects (via RT-qPCR for TNF-α and IL-6 mRNA expression).
  • Western blot analysis and immunofluorescence staining to investigate the expression of key signaling proteins involved in oxidative stress (Nrf2, HO-1) and inflammation (AMPK, p-AMPK, SIRT1, NLRP3, ASC, caspase-1, IL-1β, IL-18).
  • TUNEL staining to assess apoptosis.
  • In vivo studies using LPS-induced endotoxemia and cecal ligation and puncture (CLP) mouse models to evaluate survival rates, clinical scores, body temperature, pro-inflammatory cytokine levels (TNF-α, IL-6), multi-organ damage (serum biochemical analysis, lung index, MPO activity, H&E staining), and biodistribution of nanoparticles.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from cell cultures and animal models.

Key Insights and Ideas

  • Overcoming Shikonin's Drawbacks: The core innovation is the successful creation of Zn-Shik-PEG nanoparticles that significantly improve shikonin's water solubility and biosafety, making it a more viable therapeutic agent.
  • Dual Mechanism of Action: The nanoparticles exhibit a dual therapeutic effect: they effectively scavenge ROS via the Nrf2/HO-1 pathway and suppress inflammation by modulating the AMPK/SIRT1 pathway, thereby inhibiting NLRP3 inflammasome activation.
  • Synergistic Protection: The hybrid nanoparticle approach appears to offer synergistic benefits, enhancing the anti-inflammatory and antioxidant properties of shikonin.
  • In Vivo Efficacy: The nanoparticles demonstrate remarkable therapeutic efficacy in established animal models of sepsis, significantly improving survival rates, reducing organ damage, and mitigating inflammatory responses.
  • Targeted Organ Distribution: The nanoparticles show good distribution to key organs vulnerable in sepsis (liver, kidney, lung, spleen), suggesting sustained protective effects.

Key Results

  • Nanoparticle Characterization: Zn-Shik-PEG NPs were successfully synthesized with a uniform size of approximately 30 nm and good colloidal stability.
  • Cytotoxicity Reduction: Zn-Shik-PEG NPs showed significantly improved cell viability in LPS-stimulated macrophages compared to shikonin alone.
  • ROS Scavenging: Zn-Shik-PEG NPs were more effective at clearing intracellular ROS than shikonin.
  • Anti-inflammatory Effects: In LPS-stimulated cells, Zn-Shik-PEG NPs significantly reduced TNF-α and IL-6 mRNA expression, and modulated key inflammatory signaling pathways (AMPK/SIRT1/NLRP3).
  • Apoptosis Inhibition: Zn-Shik-PEG NPs reduced apoptosis in LPS-treated cells.
  • In Vivo Survival: In LPS-induced sepsis models, Zn-Shik-PEG NPs rescued over 67% of mice within 72 hours, compared to 17% for shikonin alone.
  • Organ Protection: Treatment with Zn-Shik-PEG NPs significantly reduced markers of liver and kidney damage (BUN, CRE, AST, ALT) and lung injury (lung index, MPO activity) in septic mice.
  • Histological Improvement: H&E staining confirmed reduced pathological damage in multiple organs of treated mice.

Limitations and Future Work

  • Toxicity of Components: While the nanoparticles improve shikonin's safety, the inherent toxicity of shikonin at higher concentrations is acknowledged. The study demonstrates reduced cytotoxicity of the nanoparticle formulation.
  • Long-term Effects: The study focuses on acute sepsis models. Further investigation into the long-term effects and potential chronic toxicity of the nanoparticles would be beneficial.
  • Clinical Translation: While promising, the transition from animal models to human clinical trials requires extensive further research and validation.
  • Mechanism Elucidation: While key pathways (Nrf2/HO-1, AMPK/SIRT1/NLRP3) are identified, a more comprehensive understanding of all molecular interactions and downstream effects could be explored.
  • Future Work: The authors suggest that Zn-Shik-PEG NPs hold therapeutic potential for other ROS-associated and inflammatory diseases, indicating a broad applicability beyond sepsis. Further studies could explore these applications.

Summary updated

Abstract

Sepsis is defined as a life-threatening organ dysfunction caused by excessive formation of reactive oxygen species (ROS) and dysregulated inflammatory response. Previous studies have reported that shikonin (Shik) possess prominent anti-inflammatory and antioxidant effects and holds promise as a potential therapeutic drug for sepsis. However, the poor water solubility and the relatively high toxicity of shikonin hamper its clinical application. To address this challenge, we constructed Zn<sup>2+</sup>-shikonin nanoparticles, hereafter Zn-Shik-PEG NPs, based on an organic-inorganic hybridization strategy of metal-polyphenol coordination to improve the aqueous solubility and biosafety of shikonin. Mechanistic studies suggest that Zn-Shik-PEG NPs could effectively clear intracellular ROS via regulating the Nrf2/HO-1 pathway, meanwhile Zn-Shik-PEG NPs could inhibit NLRP3 inflammasome-mediated activation of inflammation and apoptosis by regulating the AMPK/SIRT1 pathway. As a result, the Zn-Shik-PEG NPs demonstrated excellent therapeutic efficacies in lipopolysaccharide (LPS) as well as cecal ligation puncture (CLP) induced sepsis model. These findings suggest that Zn-Shik-PEG NPs may have therapeutic potential for the treatment of other ROS-associated and inflammatory diseases.
BibTeX
@article{guo2023zn,
  author = {Jie Guo and Yuqing Miao and Fayi Nie and Fei Gao and Hua Li and Yuan Wang and Qi Liu and Tingbin Zhang and Xiaohang Yang and Li Liu and Haiming Fan and Qiang Wang and Haifa Qiao},
  title = {{Zn-Shik-PEG nanoparticles alleviate inflammation and multi-organ damage in sepsis}},
  journal = {Journal of Nanobiotechnology},
  year = {2023},
  doi = {10.1186/s12951-023-02224-3},
}
Figure